Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03689192 · OUTCOME

Immune Responses

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors · Source last updated 2023-02-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
project blood samples were taken at baseline and every 3 months for a maximum of 1,5 year. Tumor biopsies were taken at baseline and after 3 months if possible.

What was measured

To evaluate the immunological impact of the ARG1-18,19,20 peptide vaccines using blood samples and tumor biopsies.

Analysis population: Development of a reactive T cell response against at least one of the ARG1 peptides during treatment using interferon-gamma ELISPOT

Groups in this outcome

ARG1-18,19,20 Peptide Vaccine

One ARG1-vaccine every third week for 45 weeks. ARG1-18,19,20: 300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ARG1-18,19,20 Peptide Vaccine10

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
ARG1-18,19,20 Peptide Vaccine5Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        5
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
To evaluate the immunological impact of the ARG1-18,19,20 peptide vaccines using blood samples and tumor biopsies.
groups
  1. description
    One ARG1-vaccine every third week for 45 weeks. ARG1-18,19,20: 300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide
    id
    OG000
    title
    ARG1-18,19,20 Peptide Vaccine
param Type
COUNT_OF_PARTICIPANTS
population Description
Development of a reactive T cell response against at least one of the ARG1 peptides during treatment using interferon-gamma ELISPOT
reporting Status
POSTED
time Frame
project blood samples were taken at baseline and every 3 months for a maximum of 1,5 year. Tumor biopsies were taken at baseline and after 3 months if possible.
title
Immune Responses
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice